Market capitalization | SEK113.95b |
Enterprise Value | SEK131.24b |
P/E (TTM) P/E ratio | 32.21 |
EV/FCF (TTM) EV/FCF | 20.65 |
EV/Sales (TTM) EV/Sales | 5.16 |
P/S ratio (TTM) P/S ratio | 4.48 |
P/B ratio (TTM) P/B ratio | 3.07 |
Revenue growth (TTM) Revenue growth | 19.59% |
Revenue (TTM) Revenue | SEK25.44b |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
14 Analysts have issued a Swedish Orphan Biovitrum forecast:
14 Analysts have issued a Swedish Orphan Biovitrum forecast:
Sep '24 |
+/-
%
|
||
Revenue | 25,436 25,436 |
20%
20%
|
|
Gross Profit | 16,343 16,343 |
19%
19%
|
|
EBITDA | 9,529 9,529 |
30%
30%
|
EBIT (Operating Income) EBIT | 5,784 5,784 |
29%
29%
|
Net Profit | 3,514 3,514 |
27%
27%
|
In millions SEK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceutical. The firm focuses on the hematology and immunology therapeutic areas. It also offers specialty treatments in the area of genetics and metabolism. The company was founded in 2001 and is headquartered in Solna, Sweden.
Head office | Sweden |
CEO | Guido Oelkers |
Employees | 1,772 |
Founded | 2001 |
Website | www.sobi.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.